Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pepinemab plus avelumab provides disease control in NSCLC

Publish date:: April 20, 2020

Key clinical point: Pepinemab/avelumab was well tolerated and showed antitumor activity in advanced non–small cell lung cancer patients who progressed on prior treatment.

Major finding: Disease control rates after 6 months were 59% and 81% in immunotherapy-resistant and immunotherapy-naive patients, respectively.

Study details: A phase 1b/2 trial of 50 evaluable patients.

Disclosures: The CLASSICAL-Lung trial is funded by Vaccinex and Merck. Dr. Shafique reported a consulting or advisory role with GlaxoSmithKline.

Citation:

Shafique MR et al. ASCO-SITC 2020, Abstract 75.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,